Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma-Reference-Cited by-同舟云学术

Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma

Published:2022-08 Issue:8 Volume:40 Page:385.e1-385.e8
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Zhou Li^ORCID,Liu Yiqiang,Mo Jiazhi,Cui Chuanliang,Chi Zhihong,Si Lu,Kong Yan,Yan Xieqiao,Li Siming,Wu Xiaowen,Li Juan,Xu Huayan,Cao Dengfeng,Guo Jun,Sheng Xinan^ORCID

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference32 articles.

1. Clinicopathologic and molecular pathology of collecting duct carcinoma and related renal cell carcinomas;Seo;Adv Anat Pathol,2017

2. Clinical features and prognostic outcome of renal collecting duct carcinoma: 12 cases from a single institution;Qian;Cancer Manag Res,2020

3. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan;Tokuda;J Urol,2006

4. Collecting duct carcinoma of the kidney: disease characteristics and treatment outcomes from the national cancer database;Sui;Urol Oncol,2017

5. Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish oncologic genitourinary group (SOGUG) SPAZO study;Perez-Valderrama;Ann Oncol,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishment of a nomogram to predict the overall survival of patients with collecting duct renal cell carcinoma;Discover Oncology;2024-07-04

2. Collecting Duct Carcinoma of the Kidney: A Single-Center Retrospective Study of 23 Cases;Technology in Cancer Research & Treatment;2023-01

3. Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE;Technology in Cancer Research & Treatment;2023-01